Best Natto-Serra [Discontinued] by Doctor's Best

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Angina. Although there has been interest in using oral nattokinase for angina, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Atherosclerosis. It is unclear if nattokinase is beneficial in patients with atherosclerosis. Details: Clinical research in patients at low risk for cardiovascular disease shows that taking nattokinase 2000 fibrinolytic units orally daily for a median of 3 years is not associated with any change in subclinical atherosclerosis, as measured by carotid artery intima-media thickness and carotid arterial stiffness, when compared with placebo (106406). However, a retrospective observational study of Chinese patients with hyperlipidemia and/or mild atherosclerosis has found that taking nattokinase 10,800 fibrinolytic units daily for 12 months may modulate the progression of atherosclerosis. Nattokinase use was associated with a 22% reduction in carotid artery intima-media thickness and a 36% reduction in the size of the carotid artery plaque when compared to baseline. These effects appear to be enhanced by regular exercise, avoidance of smoking and alcohol, and co-administration with aspirin (111252). The validity of these findings is limited by a lack of control group and the retrospective nature of the study.
• Cancer. Although there has been interest in using oral nattokinase for cancer, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Cardiovascular disease (CVD). Although there has been interest in using oral nattokinase for CVD, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Chronic fatigue syndrome (CFS). Although there has been interest in using oral nattokinase for CFS, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Endometriosis. Although there has been interest in using oral nattokinase for endometriosis, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Fibromyalgia. Although there has been interest in using oral nattokinase for fibromyalgia, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Hemorrhoids. Although there has been interest in using oral nattokinase for hemorrhoids, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Hyperlipidemia. It is unclear if oral nattokinase is beneficial in patients with hyperlipidemia. Details: A retrospective observational study in Chinese patients with hyperlipidemia and/or mild atherosclerosis shows that taking nattokinase 10,800 fibrinolytic units daily for 12 months is associated with a 15% to 17% improvement in total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides when compared to baseline. This effect seems to be amplified in subjects who have a higher body mass index, smoke, drink alcohol, and exercise regularly. Furthermore, the anti-hyperlipidemic effect of nattokinase appears to be enhanced by co-administration of vitamin K2 and aspirin (111252). However, the validity of these findings is limited by a lack of control group and the retrospective nature of the study. In contrast, some preliminary clinical research in patients with hyperlipidemia shows that taking nattokinase 200 mg (7000 fibrinolytic units) daily in combination with red yeast rice 1200 mg daily in divided doses for 6 months reduces LDL cholesterol and total cholesterol when compared with placebo. However, taking nattokinase alone did not improve lipid levels when compared with placebo (92312). It is likely that the lipid lowering effects of the combination are due to red yeast rice, which contains monacolin K, a chemical similar to lovastatin.
• Hypertension. It is unclear if oral nattokinase is beneficial in patients with hypertension. Details: Some clinical research suggests that nattokinase can reduce systolic blood pressure (SBP) and diastolic blood pressure (DBP). One study in patients with hypertension shows that taking nattokinase (NSK II, Japan Bio Sciences Laboratories Company Ltd.) 2000 fibrinolytic units daily for 8 weeks reduces SBP by 6 mmHg and DBP by 3 mmHg when compared with placebo (64835). In another study, taking a natto extract 30 grams daily (unknown nattokinase content) for 4 days reduces SBP and DBP by 11% and 10%, respectively, when compared with baseline (64837). However, in patients with normal blood pressure or controlled hypertension, taking nattokinase 2000 fibrinolytic units daily for a median of 3 years has no effect on blood pressure (106406).
• Impaired glucose tolerance (prediabetes). Oral nattokinase has only been evaluated in combination with other ingredients; its effect when used alone is unclear. Details: A small clinical study in patients with prediabetes shows that taking a combination product containing nattokinase 34 fibrinolytic units, chokeberry 1.64 grams, Panax ginseng 1.36 grams, and shiitake mushroom 960 mg twice daily for 12 weeks improves measures of insulin resistance, but does not reduce fasting blood glucose, postprandial glucose, or glycated hemoglobin (HbA1c), when compared with placebo (108301).
• Infertility. Although there has been interest in using oral nattokinase for infertility, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Peripheral arterial disease (PAD). Although there has been interest in using oral nattokinase for PAD, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Stroke. Although there has been interest in using oral nattokinase for stroke, there is insufficient reliable information about the clinical effects of nattokinase for this condition.
• Venous insufficiency. It is unclear if oral nattokinase is beneficial in patients with venous insufficiency. Details: A small, uncontrolled clinical study in patients with venous insufficiency who underwent vascular surgery suggests that taking nattokinase 2000 fibrinolytic units daily for 30 days after surgery may induce remission of clinical symptoms (109553). The validity of these findings is limited by a lack of control group.
• Venous thromboembolism (VTE). It is unclear if oral nattokinase is beneficial in patients with VTE. Details: A small, uncontrolled clinical study in patients with deep vein thrombosis (DVT) or phlebitis suggests that taking nattokinase 2000 fibrinolytic units daily for 30 days after a 30-day regimen of fondaparinux or enoxaparin may induce remission of clinical symptoms (109553). The validity of these findings is limited by a lack of control group and the use of anticoagulants before nattokinase therapy. Nattokinase has also been evaluated in combination with other ingredients for prophylaxis of DVT during long-haul flights. A small clinical trial shows that taking two capsules of a specific combination product (Flite Tabs, Aidan), containing 150 mg of a proprietary blend of nattokinase and maritime pine bark (Pycnogenol, Horphag Research), 2 hours before a flight and 6 hours later, might decrease the risk of DVT during long plane flights (12075). The effect of nattokinase alone on DVT risk during long-haul flights is unclear. More evidence is needed to rate nattokinase for these uses.

(Read more about NATTOKINASE)

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Bronchiectasis. A small clinical study in patients with bronchiectasis shows that taking serrapeptase 30 mg daily for 4 weeks significantly reduces frequency of cough and also seems to decrease sputum viscosity and neutrophil counts in sputum samples when compared with no treatment (13153).
• Chronic bronchitis. A small clinical study in patients with chronic bronchitis shows that taking serrapeptase 30 mg daily for 4 weeks significantly reduces frequency of cough and expectoration and also seems to decrease sputum viscosity and neutrophil counts in sputum samples when compared with no treatment (13153).
• Laryngitis. A clinical study in patients with acute or chronic ear, nose, or throat disorders, including laryngitis, shows that taking serrapeptase 10 mg three times daily reduces pain, secretions, difficulty swallowing, and body temperature after 3-4 days of treatment when compared with placebo (13152).
• Pharyngitis. A clinical study in patients with acute or chronic ear, nose, or throat disorders, including pharyngitis, shows that taking serrapeptase 10 mg three times daily reduces pain, secretions, difficulty swallowing, and body temperature after 3-4 days of treatment when compared with placebo (13152).
• Postoperative swelling. Serrapeptase has been evaluated for reducing facial swelling after a variety of procedures. A clinical study in patients undergoing maxillary antrostomy for empyema shows that taking serrapeptase 10 mg orally three times on the day before surgery, once in the evening after surgery, and three times daily for 5 days after surgery modestly reduces buccal swelling when compared with placebo (13151). In patients requiring removal of impacted mandibular third molars, a small clinical study in healthy adults suggests that taking serrapeptase 10 mg three times daily for 5 days improves postoperative trismus and swelling by the fourth postoperative day when compared with placebo; however, no difference in pain scores was observed (106013). The validity of these findings in limited by a lack of consistent comparison to baseline in both groups. Conversely, two other small studies in patients requiring removal of impacted mandibular third molars suggest that serrapeptase is less effective than dexamethasone or another proteolytic enzyme, consisting of trypsin, bromelain, and the flavonoid rutin, for improving swelling or facilitating wound healing (106011,106012). The validity of these findings is limited due to poor study methodologies.
• Rhinosinusitis. A clinical study in patients with acute or chronic ear, nose, or throat disorders, including rhinosinusitis, shows that taking serrapeptase 10 mg three times daily reduces pain, nasal secretions, nasal obstruction, and anosmia after 3-4 days of treatment when compared with placebo (13152). More evidence is needed to rate serrapeptase for these uses.

(Read more about SERRAPEPTASE)

LIKELY SAFE ...when used orally in amounts commonly found in foods. Nattokinase is a natural component of the soy food natto. It has been routinely consumed in Japan for hundreds of years (12072,12073).

POSSIBLY SAFE ...when used orally for medicinal purposes. Nattokinase has been used with apparent safety in doses of 2000 fibrinolytic units daily for up to 3 years or 10,800 fibrinolytic units daily for up to 12 months (64835,92312,106406,111252).

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about NATTOKINASE)

POSSIBLY SAFE ...when used orally and appropriately, short-term. Serrapeptase seems to be safe when used in clinical trials lasting up to 4 weeks (13151,13152,13153). There is insufficient reliable information available about the safety of serrapeptase when used long-term.

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about SERRAPEPTASE)

ANTICOAGULANT/ANTIPLATELET DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = High •  Occurrence = Possible •  Level of Evidence = D Nattokinase might increase the risk of bleeding when used with anticoagulant/antiplatelet drugs.  Details Nattokinase has thrombolytic and anticoagulant effects (12070,12073,92311). There is a case report of intracranial hemorrhage in a patient who added nattokinase to aspirin therapy (64834).

ANTIHYPERTENSIVE DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, nattokinase might increase the risk of hypotension when used with antihypertensive drugs.  Details Some clinical research suggests that nattokinase may reduce systolic and diastolic blood pressure (64835,64837).

(Read more about NATTOKINASE)

(Read more about SERRAPEPTASE)

General ...Orally, nattokinase is generally well tolerated. Preliminary clinical trials suggest that the incidence of adverse effects with nattokinase is similar to that with placebo.
Serious Adverse Effects (Rare):
Orally: Anaphylaxis, hemorrhage.

Hematologic ...Orally, nattokinase has been associated with rare reports of hemorrhage (64834,109551). A case of intracranial hemorrhage (ICH) has been reported in a 52-year-old female who took nattokinase while taking low-dose aspirin for secondary prevention of ischemic stroke. Seven days after initiating nattokinase 400 mg daily, the patient reported vertigo and unsteady gait and was diagnosed with an acute cerebellar hemorrhage. It was suggested that the thrombolytic and anticoagulant effects of nattokinase combined with aspirin's antiplatelet effects contributed to the ICH (64834). In another case, a 92-year-old female taking nattokinase daily (dose unknown) for atrial fibrillation presented to the hospital after a fall. The patient was on no other anticoagulant or antiplatelet drugs. Abdominal CT showed a ruptured hepatic cystic lesion and intraperitoneal hemorrhage, which was difficult to stop despite several transfusions of red blood cells and fresh frozen plasma. The authors attributed the bleeding complications, in part, to nattokinase use (109551).

Immunologic ...Orally, nattokinase can cause hypersensitivity reactions, including anaphylaxis, in individuals sensitive to natto (109552,111253). A case series examining hypersensitivity reactions to natto shows that the causative allergen can be either nattokinase or polygamma glutamic acid (PGA), both of which are found in the sticky substance surrounding natto soybeans. In patients with hypersensitivity to nattokinase, specifically, symptoms occurred within 2 hours after ingestion, were limited to the pharynx and larynx, and included swelling, tightness, and itching in the throat and lips and dyspnea. All patients with nattokinase sensitivity shared a history of atopic dermatitis (111253).

(Read more about NATTOKINASE)

General ...Orally, serrapeptase seems to be well-tolerated. Some patients have reported epigastric pain, gastrointestinal upset, and nausea; however, these side effects appear to occur at the same rate as placebo (13152).

Gastrointestinal ...Orally, some patients have reported experiencing epigastric pain, gastrointestinal upset, and nausea; however, these side effects appear to occur at the same rate as placebo (13152).

Immunologic ...There is a case report of bullous pemphigoid, an autoimmune subepidermal dermatosis, in an elderly man who took serrapeptase (13154).

(Read more about SERRAPEPTASE)